Cho S.-L.WEI-CHOU LINChuang C.-A.WEI-YU LIAOCHUN-FU LAI2020-07-212020-07-2120201320-5358https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085060665&doi=10.1111%2fnep.13721&partnerID=40&md5=c138d36dd4678b653e5d158a150a0744https://scholars.lib.ntu.edu.tw/handle/123456789/510264[SDGs]SDG3creatinine; epidermal growth factor receptor; erlotinib; gefitinib; linagliptin; metformin; nifedipine; prednisolone; antineoplastic agent; erlotinib; glucocorticoid; prednisolone; aged; cancer staging; cancer therapy; case report; clinical article; creatinine blood level; diabetes mellitus; disease association; drug dose reduction; drug substitution; drug withdrawal; eczema; follow up; gene mutation; human; human tissue; hypertension; hypomagnesemia; immunohistochemistry; interstitial nephritis; kidney biopsy; kidney fibrosis; laboratory test; Letter; leukocyturia; lung adenocarcinoma; male; physical examination; priority journal; protein to creatinine ratio; treatment duration; treatment response; biopsy; convalescence; drug effect; interstitial nephritis; kidney; kidney function test; lung adenocarcinoma; lung tumor; pathology; pathophysiology; procedures; treatment withdrawal; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Erlotinib Hydrochloride; Glucocorticoids; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Nephritis, Interstitial; Prednisolone; Recovery of Function; Withholding Treatmentletter10.1111/nep.137212-s2.0-85085060665